Radhika Bansal

Aug 11, 2024 | nature.com | Razan Mohty |Radhika Bansal |Urshila Durani |Madiha Iqbal |Yucai Wang |Jonas Paludo | +8 more

Dear Editor,Hemophagocytic lymphohistiocytosis (HLH) is a rare complication of chimeric antigen receptor T-cell (CAR-T) therapy [1,2,3]. With the increasing use of CAR-T therapy in treating hematological malignancies, the unique phenomenon of CAR-T-associated HLH (carHLH) is increasingly recognized. Albeit rare, reported rates vary from 1–3% to 35% depending on the underlying disease, patient population and the CAR-T product [1,2,3].

Jul 22, 2024 | nature.com | Matthew Rees |Radhika Bansal |Sikander Ailawadhi |Ricardo D. Parrondo |Saurabh Chhabra |Angela Dispenzieri | +9 more

AbstractThree classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo Clinic with commercial or investigational BDT between 2018-2023.

Jun 25, 2024 | onclive.com | Radhika Bansal

CommentaryVideoJune 25, 2024Author(s):Radhika Bansal, MBBS, discusses outpatient administration of axi-cel and brexu-cel in relapsed/refractory non-Hodgkin lymphoma. Radhika Bansal, MBBS, hematologist and oncologist, Mayo Clinic, discusses findings on the real-world outpatient administration of axicabtagene ciloleucel (axi-cel; Yescarta) and brexucabtagene autoleucel (brexu-cel; Tecartus) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma.

Aug 17, 2023 | nature.com | William Breen |Jason Young |Radhika Bansal |N. Nora Bennani |Jonas Paludo |Yucai Wang | +2 more

AbstractPET/CT is used to evaluate relapsed/refractory non-Hodgkin lymphoma (NHL) prior to chimeric antigen receptor T-cell (CAR-T) infusion at two time points: pre-leukapheresis (pre-leuk) and pre-lymphodepletion chemotherapy (pre-LD). We hypothesized that changes in PET/CT between these time points predict outcomes after CAR-T.